Rupatadine 10 mg and ebastine 10 mg in seasonal allergic rhinitis: A comparison study

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 59, Issue 7, 2004, Pages 766-771

  Guadano E M ^a   Serra Batlles, J ^a   Meseguer, J ^a   Castillo, J A ^a   De Molina, M ^a   Valero, A ^a   Picado, C ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

Antihistamine; Ebastine; Platelet activating factor; Rupatadine; Seasonal allergic rhinitis; Second generation

Indexed keywords

EBASTINE; HISTAMINE H1 RECEPTOR ANTAGONIST; PLACEBO; RUPATADINE;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ALLERGIC RHINITIS; ARTICLE; ASTHENIA; BACKACHE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FEMALE; HAY FEVER; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MULTICENTER STUDY; NASAL PRURITUS; OCULAR PRURITUS; OUTCOMES RESEARCH; PHARYNGITIS; PHARYNX DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SCORING SYSTEM; SIDE EFFECT; SNEEZING; SOMNOLENCE; STATISTICAL SIGNIFICANCE; SYMPTOM; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ANTI-ALLERGIC AGENTS; BUTYROPHENONES; CYPROHEPTADINE; DOUBLE-BLIND METHOD; FEMALE; HISTAMINE H1 ANTAGONISTS; HUMANS; MALE; MIDDLE AGED; PIPERIDINES; RHINITIS, ALLERGIC, SEASONAL; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 3042702887     PISSN: 01054538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1398-9995.2004.00576.x     Document Type: Article

References (21)

1. BOUSQUET J, VAN CAUWENBERGE P, KHALTAEV N, THE WORKSHOP EXPERT PANEL. Allergic rhinitis and its impact on asthma. In collaboration with the World Health Organization. Executive Summary of the Workshop Report, 7-10 December 1999, Geneva, Switzerland. Allergy 2002;57:841-855.
2. BOUSQUET J, VAN CAUWENBERGE P, BACHERT C. CANONICA GW, DEMOLY P, DURHAM SR et al. Requirements for medications commonly used in the treatment of allergic rhinitis. Allergy 2003;58:192-197.
3. PASSALACQUA G, BOUSQUET J, BACHERT C, CHURCH MK, BINDSLEY-JENSEN C, NAGY L et al. The clinical safety of H1-receptor antagonists. An EAACI position paper. Allergy 1996;51:666-675.
4. MYGIND N. DAHL R. Epidemiology of allergic rhinitis. Pediatr Allergy Immunol 1996;106:149-156.
5. GERGEN PJ, TURKELTAUB PC, KOVAR MG. The prevalence of allergic skin test reactivity to eight common aeroallergens in the US population: results from the second National Health and Nutrition Examination Survey. J Allergy Clin Immunol 1987;80:669-679.
6. MERLOS M, GIRALT M, BALSA D, FERRANDO R, QUERALT M, PUIGDEMONT A et al. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF). J Pharmacol Exp Ther 1997;280:114-121.
7. QUERALT M, BRAZÍS P. MERLOS M, DE MORA F, PUIGDEMONT A. In vitro inhibitory effect of rupatadine on histamine and TNF-α release from dispersed canine skin mast cells and the human cell line HMC-1. Inflamm Res 2000;49:355-360.
8. QUERALT M, BRAZÍS P, MERLOS M, PUIGDEMONT A. Inhibitory effect of rupatdine on mast cell histamine release and skin wheal development induced by Ascaris suum in hypersensitive dogs. Drug Dev Res 1998;44:49-55.
9. IZQUIERDO I, PAREDES I, LURIGADOS C, SOSPEDRA E, COOPER M, THOMAS H. A dose ranging study of rupatadine fumarate in patients with seasonal allergic rhinitis. Allergy 2000;55(Suppl. 63):275.
10. IZQUIERDO I, LURIGADOS C, PEREZ I, FORN J. Rupatadine exhibits a better profile than ebastine in patients with seasonal allergic rhinitis. Allergy 2001;56(Suppl. 68):200.
11. The Uppsala Monitoring Center. Adverse reaction terminology. Uppsala, Sweden: Uppsala Monitoring Center. 1998.
12. HURST M. SPENCER CM. Ebastine: an update of its use in allergic disorders. Drugs 2000;59:981-1006
13. RATNER PH, LIM JC, GEORGES GC. Comparison of once-daily ebastine 20 mg, ebastine 10 mg, loratadine 10 mg, and placebo in the treatment of seasonal allergic rhinitis. The Ebastine Study Group. J Allergy Clin Immunol 2000;105:1101-1107.
14. MASI M, CANDIANI R, VAN DE VENNE H. A placebo-controlled trial of cetirizine in seasonal allergic rhino-conjunctivitis in children aged 6 to 12 years. Pediatr Allergy Immunol 1993;4(Suppl. 4):47-52.
15. BOUSQUET J, VIGNOLA AM, CAMPBELL AM, MICHEL FB. Pathophysiology of allergic rhinitis. Int Arch Allergy Inmunol 1996;110:207-218.
16. GEHANNO P, BREMARD-OURY C, ZEISSER P. Comparison of ebastine to cetirizine in seasonal allergic rhinitis in adults. Ann Allergy 1996;76:507-512.
17. PEREZ I, DE LA CRUZ G, VILLA M, IZQUIERDO I. Rupatadine in allergic rhinitis: pooled analysis of efficacy data. Allergy 2002;57(Suppl. 57):245.
18. BRONSKY E, BOGGS P, FINDLAY S, GAWCHIK S. GEORGITIS J, MANSMANN H et al. Comparative efficacy. J Allergy Clin Immunol 1995;96:139-147.
19. DAVIES RJ. Efficacy and tolerability comparison of ebastine 10 and 20 mg with loratadine 10 mg: a double-blind, randomised study in patients with perennial allergic rhinitis. Clin Drug Invest 1998;16:413-420.
20. SPAETH J, KLIMEK L, MÖSGES R. Sedation in allergic rhinitis is caused by the condition and not by antihistamine treatment. Allergy 1996;51:893-906.
21. LURIGADOS C, IZQUIERDO I, PAREDES I. GARCÍA-GEA C, MORTE A, BARBANOJ MJ. Central and peripheral CNS evaluation of rupatadine fumarate: a new H1-antihistamine and PAF antagonist. Allergy 2000;55(Suppl. 63):275.